author-photo

Petra Deegen

Amgen

13

Papers

354

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
The PSMA Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (14)
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (16)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (153)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

2012 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (98)
Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)